Related Experiment Video
Updated: Jun 20, 2026
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Transcriptome-wide Mendelian randomization and single-cell analysis during CD4+ T cell activation deciphers
Kai Cui1, Qiuming Zou1, Xinyi Qu1
1State Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, China.
Abstract:
Immunotherapy has become a promising treatment for various cancers, including colorectal cancer (CRC). Despite significant progress, identifying immune cell-specific therapeutic targets remains challenging, especially for CD4+ T cells, whose activation influences both anti-tumor and pro-tumor immune responses. This study aims to identify potential immunotherapy targets for CRC by exploring the causal relationships between CD4+ T cell activation-associated genes and CRC through Mendelian randomization (MR) and single-cell RNA sequencing (scRNA-seq). We used transcriptome-wide MR, summary-based MR (SMR), and colocalization analysis, along with validation through multi-omics approaches, to identify 28 dynamic CD4+ T cell-related genes as therapeutic targets. Notably, PARP14 and ORMDL3 emerged as key targets, with strong associations to immune therapy resistance and CRC. This research highlights the critical role of CD4+ T cell activation in CRC progression and identifies novel potential targets for immunotherapy.
Insights
This study identifies CD4+ T cell genes as potential immunotherapy targets for colorectal cancer (CRC). PARP14 and ORMDL3 show promise for overcoming immune therapy resistance in CRC.
Area of Science:
- Immunology
- Genetics
- Oncology
Background:
- Immunotherapy is a key treatment for colorectal cancer (CRC).
- Identifying specific immune cell targets, particularly CD4+ T cells, is crucial for effective cancer immunotherapy.
- CD4+ T cell activation impacts both anti-tumor and pro-tumor immunity in CRC.
Purpose of the Study:
- To identify novel immunotherapy targets for CRC by investigating causal links between CD4+ T cell activation genes and CRC.
- To explore the role of CD4+ T cell dynamics in CRC progression and immune evasion.
Main Methods:
- Utilized Mendelian randomization (MR) including transcriptome-wide MR and summary-based MR (SMR).
- Employed colocalization analysis and single-cell RNA sequencing (scRNA-seq).
- Validated findings through multi-omics approaches.
Main Results:
- Identified 28 dynamic CD4+ T cell-related genes as potential therapeutic targets for CRC.
- PARP14 and ORMDL3 were highlighted as key targets associated with immune therapy resistance.
- Demonstrated significant causal relationships between specific CD4+ T cell genes and CRC development.
Conclusions:
- CD4+ T cell activation plays a critical role in colorectal cancer progression.
- PARP14 and ORMDL3 represent promising novel targets for enhancing immunotherapy efficacy in CRC.
- This research provides a foundation for developing targeted immunotherapies for colorectal cancer.
More Related Videos
10:13A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
09:08Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
